MASON, OH; February 8, 2019
Prasco Laboratories announced today the launch of the Authorized Generic of ADVAIR DISKUS (fluticasone propionate and salmeterol inhalation powder). This is the latest prescription medication in Prasco’s line of Authorized Generics in partnership with GSK. Under the terms of the agreement, all three strengths of fluticasone propionate and salmeterol inhalation powder, 100/50, 250/50 and 500/50 mcg using the DISKUS inhaler will be distributed in the U.S. under the Prasco label.
This launch marks the first time a generic version of ADVAIR DISKUS (fluticasone propionate and salmeterol inhalation powder) is available in the United States. “We are pleased to provide millions of patients the trusted brand of ADVAIR DISKUS as an authorized generic,” said Prasco Chief Executive Officer Chris Arington. “The Prasco authorized generic, fluticasone propionate and salmeterol Inhalation Powder will provide patients with the same quality and experience as the brand product. A unique and exciting part of this launch is that the DISKUS inhaler itself will also be identical,” stated Arington. “We are grateful to expand our relationship with a leader in the industry like GSK.”
GSK and DISKUS are registered trademarks of the GSK group of companies.
Prasco, the Authorized Generic Company, is a privately held healthcare company located in Mason, Ohio. Over 50 of the most innovative and trusted brand companies have relied on Prasco to bring their products to the generic marketplace as Authorized Generics. As the acknowledged category leader, Prasco has launched over 90 Authorized Generics, providing patients with brand quality at more affordable prices in over 60,000 pharmacies nationwide.
For more information, please see Full Prescribing and Patient Information.